Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuo Therapeutics, Inc.AURX · Entity 7149 | Director · CEO/CFO | August 27, 2026 | August 31, 2026 |
| PLx Pharma Inc.PLXP · Entity 129056 | Acting Chief Financial Officer · 10% owner | June 14, 2017 | June 16, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuo Therapeutics, Inc.
Report date August 27, 2026 · Filed August 31, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,070,000 |
Last balance in matching sequence
After 2026-08-28 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-27 · Purchase · Acquired 789 · Balance 2,062,016 Row 2 · 2026-08-28 · Purchase · Acquired 7,984 · Balance 2,070,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.
PLx Pharma Inc.
Report date June 14, 2017 · Filed June 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,913 |
Reported balance
After 2017-06-14 transaction · row 1
1 source rowRow 1 · 2017-06-14 · Purchase · Acquired 32,727 · Balance 151,913 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2027-06-14 | Direct | 32,727 |
Reported balance
After 2017-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-14 · Purchase · Acquired 32,727 · Balance 32,727 F1: Issued pursuant to a private placement in connection with the purchase of common stock in a registered direct offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued pursuant to a private placement in connection with the purchase of common stock in a registered direct offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2017 Filed Jan 12, 2017 01:19 UTC | Nuo Therapeutics, Inc. NONE · Entity 7149 | GrantOption to purchase Common Stock · Derivative | 162,500 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001144204-17-001882 · v456665_4.xml · derivative · entry 1 JORDEN DAVID EMERSON · CIK 0001313516 · Director · CEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2026-07-01 F1 · date: The grant of these options was approved by the issuer's board of directors on July 1, 2016, subject to stockholder approval of the 2016 Omnibus Incentive Compensation Plan under which the options were granted. Stockholder approval was obtained by means of a written consent and the issuer filed a related Information Statement on Schedule 14C with the SEC on November 25, 2016. The stockholder approval became effective on January 9, 2017. The option grant disclosed herein does not include options to purchase 187,500 shares subject to performance conditions, which have not yet vested and are therefore not yet reportable on Form 4. F2 · derivative.exercise_date: Of these options, 62,500 vested immediately, and 50,000 each will vest on 3/31/17 and 12/31/17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.